The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Zomig Rapimelt 2.5 mg orodispersible Tablets

IMED Healthcare Ltd.PPA1463/168/002

Main Information

Trade NameZomig Rapimelt 2.5 mg orodispersible Tablets
Active SubstancesZolmitriptan
Dosage FormOrodispersible tablet
Licence HolderIMED Healthcare Ltd.
Licence NumberPPA1463/168/002

Group Information

ATC CodeN02CC Selective serotonin (5HT1) agonists
N02CC03 zolmitriptan


License statusAuthorised
Licence Issued04/06/2021
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back